Business
Kalytera Announces Grant of Stock Options
Kalytera Announces Grant of Stock Options.
About this update from Claritas Pharmaceuticals Inc.
[{"type":"text","content":"\n\n SAN FRANCISCO and TEL AVIV, Israel, Jan. 31, 2018 (GLOBE NEWSWIRE) -- Kalytera Therapeutics, Inc. (TSX VENTURE:KALY) (OTCQB:KALTF) (the \"Company\" or \"Kalytera\") today announced that it has granted stock options on January 30, 2018 to certain directors and officers of the Company.  The stock options have an exercise price of $0.38 per common share and expire ten years from the date of grant.  One-third of the options granted will vest on January 30, 2019 and the remaining options will vest in twenty-four (24) equal monthly installments commencing February 2019.  Stock options to purchase 326,000 common shares of Kalytera were issued to each of Ron Erickson, Jeff Paley and Gary Leong, who are all independent members of the Company’s board of directors, and stock options to purchase 1,045,210 common shares of Kalytera were issued to Robert Farrell, a director and the Chief Executive Officer of the Company.\n About Kalytera Therapeutics Kalytera Therapeutics, Inc. (\"Kalytera\") is pioneering the development of a next generation of cannabinoid therapeutics. Through its proven leadership, drug development expertise, and intellectual property portfolio, Kalytera seeks to establish a leading position in the development of novel cannabinoid medicines for a range of important unmet medical needs, with an initial focus on graft versus host disease (“GVHD”) . Kalytera also intends to develop a new class of proprietary cannabidiol (\"CBD\") therapeutics. CBD is a versatile compound that has shown activity against a number of pharmacological targets. However, there are limitations associated with natural CBD, including its poor oral bioavailability. Kalytera will seek to develop innovative CBD formulations and prodrugs in an effort to overcome these limitations, and to target specific disease sites within the body. Kalytera intends to file composition of matter and method of use patents covering its novel inventions, with the goal of limiting future competition. Website Home: https://kalytera.co/News and Insights: https://kalytera.co/news/Investors: https://kalytera.co/investors/ Cautionary Statements Neither TSX Venture Exchange nor its Regulation Services Provider (as that term is defined in the policies of the TSX Venture Exchange) accepts responsibility for the adequacy or accuracy...